12:32 Thu 23 Apr 2020
Redx Pharma plc - Result of AGM and operational update
("Redx" or "the Company")
Result of Annual General Meeting and operational update
The table below sets out the details of the votes put to shareholders
Resolution number |
Resolution name |
Number of votes for & discretionary |
% of votes for & discretionary |
Number of votes against |
% of votes against |
% of votes witheld |
Total votes cast (including withheld) |
1 |
Receive the Company's annual accounts |
112,563,705 |
100% |
Nil |
Nil% |
Nil% |
112,567,612 |
2 |
Re-appoint RSM as auditors |
112,505,053 |
99.95% |
58,652 |
0.05% |
Nil% |
112,567,612 |
3 |
Elect Dr |
112,503,567 |
99.94% |
63,138 |
0.06% |
Nil% |
112,567,612 |
4 |
Re-elect |
112,503,567 |
99.94% |
63,138 |
0.06% |
Nil% |
112,567,612 |
5 |
Re-elect Dr |
112,433,567 |
99.94% |
63,138 |
0.06% |
0.06% |
112,567,612 |
6 |
Authorise the directors to allot shares |
112,472,738 |
99.92% |
93,967 |
0.08% |
Nil% |
112,567,612 |
7 |
Disapply pre-emption rights |
112,472,515 |
99.92% |
93,967 |
0.08% |
Nil% |
112,567,612 |
Since the announcement of the preliminary annual results on
Secondly, the Company now confirms that, following the 30 March announcement regarding the agreement of a
Furthermore, the Company and Redmile are continuing their discussions with regards to Redmile's stated intention to provide further long-term funding to the business. Further announcements will be made in due course.
Operationally, Redx remains focused on its strategy of discovering and developing novel drugs with the potential to transform the treatment of cancer and fibrosis. Despite the impact of and restrictions related to the COVID-19 pandemic, the majority of the Company's operations in the discovery phase, preclinical phase, and in ongoing research collaborations are continuing to plan, through efforts such as the effective use of outsourced contract research organisations (CROs) in multiple countries. This situation may change, should CRO operations become operationally affected.
Redx confirms, however, that recruitment to its phase 1/2a clinical trial of RXC004, an oral porcupine inhibitor, has been halted in line with the policy of the five recruiting hospital centres in the
For further information, please contact:
|
T: +44 1625 469 918 |
|
|
|
|
|
T: +44 20 7894 7000 |
|
|
|
|
|
T: +44 20 3705 9330 |
Claes Spång/ |
|
|
|
FTI Consulting |
T: +44 20 3727 1000 |
|
|
About
Redx is a
If you would like to sign up to regular alerts from
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE